Sanofi (SNY) News Today $47.86 +0.65 (+1.37%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Sanofi stops supply of high cholesterol drug to China due to limited availabilityAugust 12 at 6:14 AM | reuters.comCitigroup Inc. Acquires 180,127 Shares of Sanofi (NASDAQ:SNY)August 12 at 4:51 AM | marketbeat.comAnalyzing Sanofi (NASDAQ:SNY) and Roche (OTCMKTS:RHHBY)August 12 at 2:47 AM | americanbankingnews.comSanofi (NASDAQ:SNY) Shares Sold by Invesco Ltd.August 11 at 5:12 AM | marketbeat.comSanofi (NASDAQ:SNY) Upgraded at JPMorgan Chase & Co.August 11 at 2:05 AM | americanbankingnews.comManhattan West Asset Management LLC Increases Stake in Sanofi (NASDAQ:SNY)August 10 at 7:11 AM | marketbeat.comZions Bancorporation National Association UT Invests $11.50 Million in Sanofi (NASDAQ:SNY)August 9 at 8:42 AM | marketbeat.comSanofi (NASDAQ:SNY) Upgraded by JPMorgan Chase & Co. to Overweight RatingAugust 9 at 8:30 AM | marketbeat.comSanofi (NASDAQ:SNY) Shares Sold by Primecap Management Co. CAAugust 8, 2025 | marketbeat.comSanofi’s SAR444881 Study Terminated: Implications for InvestorsAugust 7, 2025 | msn.comRegeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP TreatmentAugust 7, 2025 | msn.comSanofi’s New Asthma Treatment Study: Potential Market Game-ChangerAugust 7, 2025 | msn.comSanofi’s Asthma Study: A Long-term Look at Lunsekimig’s PotentialAugust 7, 2025 | msn.comSanofi Finalizes Acquisition of Vigil Neuroscience to Boost Neurology PipelineAugust 7, 2025 | tipranks.comSanofi’s Teplizumab Study in Japan: A Potential Game-Changer for Type 1 DiabetesAugust 7, 2025 | tipranks.comSanofi’s Promising Phase 2 Study on Crohn’s Disease TreatmentAugust 7, 2025 | tipranks.comSanofi’s SAR443579 Study Terminated: Implications for Hematological Cancer TreatmentAugust 7, 2025 | tipranks.comSanofi’s Phase 3 Study on Tolebrutinib: A Potential Game-Changer for Multiple SclerosisAugust 7, 2025 | tipranks.comSanofi: Playing To WinAugust 7, 2025 | seekingalpha.comPNC Financial Services Group Inc. Increases Holdings in Sanofi (NASDAQ:SNY)August 7, 2025 | marketbeat.comSanofi’s Teplizumab Study: A Potential Game-Changer for Type 1 Diabetes TreatmentAugust 6, 2025 | theglobeandmail.comSanofi (NASDAQ:SNY) Shares Sold by Westfield Capital Management Co. LPAugust 6, 2025 | marketbeat.comPress Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.August 6, 2025 | globenewswire.comSanofi (SNY) Price Target Reduced by Deutsche Bank AnalystAugust 5, 2025 | gurufocus.comSanofi’s New Study on Teplizumab: A Potential Game-Changer for Type 1 Diabetes in JapanAugust 5, 2025 | tipranks.comSanofi’s SAR443579 Study Terminated: Implications for InvestorsAugust 5, 2025 | tipranks.comSanofi’s Tolebrutinib Study: A Step Forward in Multiple Sclerosis TreatmentAugust 5, 2025 | tipranks.comFY2025 EPS Estimates for Sanofi Reduced by Leerink PartnrsAugust 5, 2025 | americanbankingnews.comSanofi (NASDAQ:SNY) Upgraded at Wall Street ZenAugust 5, 2025 | americanbankingnews.comSanofi Stock: Attractive Valuation and Upcoming Catalysts Support Buy Rating Despite Adjusted Financial ForecastsAugust 4, 2025 | tipranks.comLeerink Partnrs Issues Negative Estimate for Sanofi EarningsAugust 4, 2025 | marketbeat.comSanofi’s Earnings Call Highlights Strong Growth and OptimismAugust 3, 2025 | theglobeandmail.comSanofi (NASDAQ:SNY) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPSAugust 3, 2025 | marketbeat.comArkadios Wealth Advisors Has $1.20 Million Stock Position in Sanofi (NASDAQ:SNY)August 3, 2025 | marketbeat.comFoundations Investment Advisors LLC Makes New $339,000 Investment in Sanofi (NASDAQ:SNY)August 3, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Upgraded to "Buy" at Wall Street ZenAugust 3, 2025 | marketbeat.comEU Approves Sanofi’s (SNY) Sarclisa for Newly Diagnosed Multiple Myeloma PatientsAugust 2, 2025 | msn.comProVise Management Group LLC Increases Position in Sanofi (NASDAQ:SNY)August 2, 2025 | marketbeat.comSanofi India Reports Growth in Operating Profit Amid Sales DeclineAugust 2, 2025 | tipranks.comArrowhead Pharmaceuticals (ARWR) and Sanofi Ink Deal for Plozasiran in ChinaAugust 1, 2025 | gurufocus.comDupixent sales spur Sanofi growth, but profits fall shortAugust 1, 2025 | finance.yahoo.comSanofi’s Amlitelimab Study: A Potential Game-Changer for Atopic Dermatitis TreatmentAugust 1, 2025 | tipranks.comSanofi (NASDAQ:SNY) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comSanofi (NASDAQ:SNY) Sets New 1-Year Low - What's Next?August 1, 2025 | marketbeat.comSanofi’s Latest Vaccine Study: A Potential Game-Changer in Respiratory HealthAugust 1, 2025 | tipranks.comRegeneron and Sanofi’s Dupilumab Study: A Real-World Asthma Treatment AnalysisAugust 1, 2025 | tipranks.comSanofi’s TZIELD® Study: A Closer Look at Long-term Safety in Stage 2 Type 1 DiabetesAugust 1, 2025 | tipranks.comEuropean pharmaceutical stocks slip after Trump pushes for lower drug pricesAugust 1, 2025 | msn.comRegeneron posts Q2 beat as new Eylea version outperformsAugust 1, 2025 | msn.comArrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to SanofiAugust 1, 2025 | businesswire.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address SNY Media Mentions By Week SNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNY News Sentiment▼0.500.75▲Average Medical News Sentiment SNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNY Articles This Week▼3026▲SNY Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NVS News AZN News NVO News GSK News TAK News ARGX News ONC News BNTX News INSM News SMMT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNY) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access